Brief: Valneva's Chikungunya Vaccine Authorized In EU For Adolescents Aged 12 And Above
01/04/2025 16:47
April 1 (Reuters) - Valneva SE VLS.PA: VALNEVA’S CHIKUNGUNYA VACCINE IXCHIQ® NOW AUTHORIZED IN EU FOR ADOLESCENTS AGED 12 AND ABOVE IXCHIQ VACCINE NOW AVAILABLE FOR ADOLESCENTS IN EU, NORWAY, LIECHTENSTEIN, ICELAND Source text: ID:nGNX8VvJ8R Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency